← FDA DRUG APPROVALS

FDA ANDA · ANDA206081

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE

Sponsor: SUN PHARM

APPLICATION
ANDA206081
TYPE
ANDA
ORIGINAL APPROVAL
2023-07-31
LATEST ACTION
2023-07-31
ROUTE
ORAL
DOSAGE FORM
TABLET, EXTENDED RELEASE
MARKETING STATUS
Discontinued

Products

SAXAGLIPTIN AND METFORMIN HYDROCHLORIDEDiscontinued
METFORMIN HYDROCHLORIDE 1GM, SAXAGLIPTIN HYDROCHLORIDE EQ 5MG BASE · TABLET, EXTENDED RELEASE · ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDEDiscontinued
METFORMIN HYDROCHLORIDE 500MG, SAXAGLIPTIN HYDROCHLORIDE EQ 5MG BASE · TABLET, EXTENDED RELEASE · ORAL
SAXAGLIPTIN AND METFORMIN HYDROCHLORIDEDiscontinued
METFORMIN HYDROCHLORIDE 1GM, SAXAGLIPTIN HYDROCHLORIDE EQ 2.5MG BASE · TABLET, EXTENDED RELEASE · ORAL

Approval history

2023-07-31UNKNOWN · Original · standard — Letter ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →